"New York Oncology Hematology (NYOH) is the leading provider of community-based cancer care and blood disorder services. With six convenient locations in Albany, Amsterdam, Clifton Park in Saratoga County, Hudson, and Troy, our team of 35 physicians and more than 350 cancer care specialists see more than 100,000 cancer visits a year."

During the past decade, New York Oncology Hematology PC - Amsterdam conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 15 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 8 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New York Oncology Hematology PC - Amsterdam" #1 sponsor was "National Cancer Institute (NCI)" with 9 trials, followed by "NSABP Foundation Inc" with 6 trials sponsored, "Alliance for Clinical Trials in Oncology" with 1 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 1 trials sponsored and "GOG Foundation" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New York Oncology Hematology PC - Amsterdam" #1 collaborator was "National Cancer Institute (NCI)" with 7 trials as a collaborator, "Cancer and Leukemia Group B" with 3 trials as a collaborator, "North Central Cancer Treatment Group" with 3 trials as a collaborator, "SWOG Cancer Research Network" with 3 trials as a collaborator and "American College of Surgeons" with 2 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "New York Oncology Hematology PC - Amsterdam" are "Breast Cancer" (6 trials), "Breast Adenocarcinoma" (2 trials), "Stage IA Breast Cancer AJCC v7" (2 trials), "Stage IB Breast Cancer AJCC v7" (2 trials) and "Stage IIA Breast Cancer AJCC v6 and v7" (2 trials). Many other conditions were trialed in "New York Oncology Hematology PC - Amsterdam" in a lesser frequency.

Most popular intervention types in "New York Oncology Hematology PC - Amsterdam" are "Drug" (16 trials), "Other" (10 trials), "Biological" (8 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (7 trials), "Quality-of-Life Assessment" (6 trials), "Cyclophosphamide" (4 trials), "Paclitaxel" (4 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "New York Oncology Hematology PC - Amsterdam" are 10 trials for "Female" genders and 8 trials for "All" genders.

Currently, there are NaN active trials in "New York Oncology Hematology PC - Amsterdam". undefined are not yet recruiting, undefined are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in New York Oncology Hematology PC - Amsterdam, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in New York Oncology Hematology PC - Amsterdam, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".